Traditional organoid culture can present challenges for the downstream analysis of single organoids. In this webinar, Dr. Allysa Stern will discuss a unique workflow that enables clonal organoid development, monitoring of iPSC differentiation over time and automated isolation of single organoids.

Dr. Scott Magness will then present a case related to his group’s work investigating tumor cell heterogeneity through clonal organoid morphology and transcriptomics. He will discuss new approaches using single organoid transcriptomics to evaluate organoids derived from single cells from gastric dysplastic tissues and how this approach might reveal new ways to investigate tumor cell heterogeneity and evasion of some cells from cancer treatments.

As a cornerstone of genetic analysis in biological research, quantitative PCR (qPCR) and digital PCR (dPCR) are the most sensitive molecular methods to analyze nucleic acids and play a key role in the development of cell and gene therapies (CGT).

These tools are widely used during CGT development for example in biodistribution, pharmacokinetics and pharmacodynamics of the investigational lead molecule. But many samples, including tissues rich in nucleases, lipids and other inhibiting substances and target molecules that are short or contain modified bases, can be challenging to work with. For these types of samples, assay design using advanced strategies, concentration standards, spike-in controls and validated normalization is key for reliable analyses.

In this webinar, Dr. Kubista will present strategies for implementing reliable qPCR and dPCR analysis in CGT development while highlighting best practices for adhering to MIQE and dMIQE guidelines and the recently released ISO standard, ISO 20395:2019.

Join us for an exclusive webinar focused on psilocybin licensing and compliance with expert speaker Ryan Pincura, Director of Regulatory Affairs at Tendrel Group.

Asset Management has traditionally been built for large pharma companies. But with advancements in technology, that is no longer true. Asset management programs are available for all companies, regardless of size.

In today’s world, laboratories are constantly pushed to be faster, more effective, more accurate, with less waste and cost. At the same time emerging technologies provide labs with an opportunity to change the way they work today making them more efficient and effective. Leveraging these technologies will determine the success of your lab to evolve into the lab of tomorrow.

Most organizations now recognize digitalization as a necessity for the lab of the future, yet many find it difficult to justify the expense, get stakeholder buy-in, or move the process forward. The delay carries significant risks – anything from untraceable data, lost protocols, to non-compliance of regulatory requirements on data integrity. It also takes away the opportunities to automate, scale up, and integrate lab processes efficiently.